Amendment To Collaboration Agreement Sample Contracts

Sixth Amendment to Collaboration Agreement (March 7th, 2018)

This Sixth Amendment ("Sixth Amendment") to the Collaboration Agreement (the "Agreement") by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070, Basel, Switzerland, and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (together, "Roche"), on the one hand, and Foundation Medicine, Inc., with an office and place of business at 150 Second Street, Cambridge, MA 02141, U.S.A. ("FMI"), on the other hand (each a "Party," and collectively, the "Parties"), as such Agreement has been amended from time to time, is entered into by and between the Parties and shall be considered effective as of the 1st of November, 2017 (the "Sixth Amendment Effective Date"). Capitalized terms used in this Sixth Amendment and not otherwise defined herein are used with the meanings ascribed to them in the Agreement.

RE:Amendment to Collaboration Agreement; Extension of Research Term (March 5th, 2018)

As you know, Astellas Pharma Inc. ("Astellas") and Cytokinetics, Inc. ("Cytokinetics") are parties to that certain Amended and Restated License and Collaboration Agreement dated December 22, 2014, as amended by the Amendment to the Amended and Restated License and Collaboration Agreement dated July 27, 2016 and the Amendment to Collaboration Agreement dated April 11, 2017 (as so amended, the "Collaboration Agreement"). Capitalized terms used in this letter and not otherwise defined shall have the meaning ascribed to them in the Collaboration Agreement. The Parties hereby agree to amend the Collaboration Agreement as follows, effective as of the date first set forth above:

Fifth Amendment to Collaboration Agreement (September 13th, 2017)

This Fifth Amendment (Fifth Amendment) to the Collaboration Agreement (the Agreement) by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070, Basel, Switzerland, and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (together, Roche), on the one hand, and Foundation Medicine, Inc., with an office and place of business at 150 Second Street, Cambridge, MA 02141, U.S.A. (FMI), on the other hand (each a Party, and collectively, the Parties), as such Agreement has been amended from time to time, is entered into by and between the Parties and shall be considered effective as of the 8th of September, 2017 (the Fifth Amendment Effective Date). Capitalized terms used in this Fifth Amendment and not otherwise defined herein are used with the meanings ascribed to them in the Agreement.

RE:Amendment to Collaboration Agreement; Payment Mechanism Under Section [*] (August 4th, 2017)

As you know, Astellas Pharma Inc. ("Astellas") and Cytokinetics, Inc. ("Cytokinetics") are parties to that certain Amended and Restated License and Collaboration Agreement dated December 22, 2014 (the "Collaboration Agreement"), as amended, including the amendment dated July 27, 2016 (the "2016 Amendment"). Capitalized terms used in this letter and not otherwise defined will have the meaning ascribed in the Collaboration Agreement. The Parties hereby agree to amend the Collaboration Agreement as follows, effective as of April 1, 2017:

Fourth Amendment to Collaboration Agreement (March 3rd, 2017)

This Fourth Amendment ("Fourth Amendment") to the Collaboration Agreement (the "Agreement") by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070, Basel, Switzerland, and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (together, "Roche"), on the one hand, and Foundation Medicine, Inc., with an office and place of business at 150 Second Street, Cambridge, MA 02141, U.S.A. ("FMI"), on the other hand (each a "Party," and collectively, the "Parties"), as such Agreement was amended by the First Amendment to the Collaboration Agreement dated April 6, 2016 ("First Amendment"), the Second Amendment to the Collaboration Agreement dated June 16, 2016 ("Second Amendment"), and the Third Amendment to the Collaboration Agreement, dated July 25, 2016 ("Third Amendment"), is entered into by and between the Parties and shall be considered effective as of the 20th of D

Third Amendment to Collaboration Agreement (November 2nd, 2016)

This Third Amendment ("Third Amendment") to the Collaboration Agreement (the "Agreement") by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070, Basel, Switzerland, and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (together, "Roche"), on the one hand, and Foundation Medicine, Inc., with an office and place of business at 150 Second Street, Cambridge, MA 02141, U.S.A. ("FMI"), on the other hand (each a "Party," and collectively, the "Parties"), as such Agreement was amended by the First Amendment to the Collaboration Agreement dated April 6, 2016 ("First Amendment") and the Second Amendment to the Collaboration Agreement dated June 16, 2016, is entered into by and between the Parties and shall be considered effective as of the 25th of July, 2016 (the "Third Amendment Effective Date"). Capitalized terms used in this Third Amendment and not otherwise de

First Amendment to Collaboration Agreement (August 3rd, 2016)

This First Amendment ("First Amendment") to the Collaboration Agreement (the "Agreement") by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070, Basel, Switzerland, and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (together, "Roche"), on the one hand, and Foundation Medicine, Inc., with an office and place of business at 150 Second Street, Cambridge, MA 02141, U.S.A. ("FMI"), on the other hand (each a "Party," and collectively, the "Parties"), is entered into by and between the Parties and shall be considered effective as of the 6th of April, 2016 (the "First Amendment Effective Date"). Capitalized terms used in this First Amendment and not otherwise defined herein are used with the meanings ascribed to them in the Agreement.

Second Amendment to Collaboration Agreement (August 3rd, 2016)

This Second Amendment ("Second Amendment") to the Collaboration Agreement (the "Agreement") by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070, Basel, Switzerland, and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (together, "Roche"), on the one hand, and Foundation Medicine, Inc., with an office and place of business at 150 Second Street, Cambridge, MA 02141, U.S.A. ("FMI"), on the other hand (each a "Party," and collectively, the "Parties"), as such Agreement was amended by the First Amendment to the Collaboration Agreement dated April 6, 2016 ("First Amendment"), is entered into by and between the Parties and shall be considered effective as of the 16th of June, 2016 (the "Second Amendment Effective Date"). Capitalized terms used in this Second Amendment and not otherwise defined herein are used with the meanings ascribed to them in the Agreemen

Discovery Laboratories, Inc. – Second Amendment to Collaboration Agreement (April 5th, 2016)

This Second Amendment ("Amendment") to Collaboration Agreement dated as of October 10, 2014, as amended on August 4, 2015 (the "Agreement") is made and entered into as of March 31, 2016 (the "Amendment Date") by and between DISCOVERY LABORATORIES, INC., a corporation organized and existing under the laws of the state of Delaware having its principal place of business at 2600 Kelly Road, Suite 100, Warrington, PA 18976 USA ("Discovery Labs"), and BATTELLE MEMORIAL INSTITUTE, through its Corporate Operations, a corporation organized and existing under the laws of the state of Ohio having its principal place of business at 505 King Avenue, Columbus, Ohio 43201-2693, USA ("Battelle").

Alphatec Holdings – First Amendment to Collaboration Agreement (March 15th, 2016)

This First Amendment to the Collaboration Agreement (the "Amendment") is entered into as of November 3, 2015 (the "Amendment Effective Date"), ") is by and among Alphatec Spine, Inc., a California corporation ("Company"), a wholly-owned subsidiary of Alphatec Holdings, Inc., a Delaware corporation ("Holdings"), Elite Medical Holdings, LLC a Nevada limited liability company ("Elite") and Pac 3 Surgical Products, LLC ("Pac 3"), a Nevada limited liability company (collectively, Elite and Pac 3 shall be referred to as the "Consultant").

Supplemental Agreement Regarding Cdx Agreement and Collaboration Agreement and Sixth Amendment to Collaboration Agreement (February 26th, 2016)

This Supplemental Agreement Regarding CDx Agreement and Collaboration Agreement And Sixth Amendment to Collaboration Agreement (this "Supplemental Agreement") is entered into as of January 6, 2016 (the "Effective Date") by and among Medivation, Inc., a Delaware corporation having offices located at 525 Market Street, 36th Floor, San Francisco, CA 94105, United States, its wholly owned subsidiary Medivation Prostate Therapeutics, Inc., a Delaware corporation having offices located at [the same location] (such entities, collectively, "Medivation"), Astellas Pharma Inc., a Japanese corporation having offices located at 2-5-1, Nihonbashi Honcho, Chuo Ku, Tokyo 103- 8411, Japan ("API") and its indirect wholly owned subsidiary Astellas US LLC, a Delaware limited liability company having office located at 1 Astellas Way, Northbrook, Illinois 60062, United States (collectively with API, "Astellas"). Medivation and Astellas are sometimes referred to herein individually as a "Party" and colle

2304101 Ontario Inc. – Amendment to Collaboration Agreement (November 16th, 2015)

THIS AMENDMENT (the "Amendment") is made effective as of January 1, 2014 (the "Effective Date"), by and between the Ontario Brain Institute ("OBI"), Behaviour Neurological Applications and Solutions ("Company"), and The Hospital for Sick Children ("Hospital"), located at 555 University Avenue, Toronto, Ontario, Canada (collectively, the "Parties").

Discovery Laboratories, Inc. – First Amendment to Collaboration Agreement (August 10th, 2015)

This First Amendment ("Amendment") to Collaboration Agreement dated as of October 10, 2014 (the "Agreement") is made and entered into as of August 4, 2015 (the "Amendment Date") by and between DISCOVERY LABORATORIES, INC., a corporation organized and existing under the laws of the state of Delaware having its principal place of business at 2600 Kelly Road, Suite 100, Warrington, PA 18976 USA ("Discovery Labs"), and BATTELLE MEMORIAL INSTITUTE, through its Corporate Operations, a corporation organized and existing under the laws of the state of Ohio having its principal place of business at 505 King Avenue, Columbus, Ohio 43201-2693, USA ("Battelle").

First Amendment to Collaboration Agreement (April 10th, 2015)

This First Amendment to the Collaboration Agreement (this "Amendment") is made as of August 19, 2014 (the "Effective Date"), by and among PROLIAS TECHNOLOGIES INC., a Delaware corporation ("Prolias") and PDI, INC., a Delaware corporation ("PDI"). Each of Prolias and PDI are referred to herein as a "Party" and together as the "Parties."

First Amendment to Collaboration Agreement (November 5th, 2014)

STOCK PURCHASE AGREEMENT, dated as of ______ __, ____ by and among [PDI, INC., a Delaware corporation] (the "Buyer") and the individuals identified on the signature page hereto (collectively, the "Sellers").

Receptos Inc. – First Amendment to Collaboration Agreement (December 10th, 2013)

This FIRST AMENDMENT (the First Amendment), dated as of December 6, 2013 (the Amendment Date), to that certain Collaboration Agreement dated December 5, 2011 (the Agreement) by and between Receptos, Inc. (Receptos), a Delaware corporation located at 10835 Road to the Cure, Suite #205, San Diego, California 92121, USA and Ono Pharmaceutical Co., Ltd. (ONO), a corporation organized under the laws of Japan, having its principal place of business at 8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka 541-8564, Japan, is entered into by Receptos and ONO (each individually, a Party and collectively, the Parties) and is deemed effective as of the Amendment Date. Capitalized terms used but not otherwise defined herein shall have the meanings provided in the Agreement.

Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Triple Asterisks Denote Omissions. FIRST AMENDMENT TO COLLABORATION AGREEMENT (September 4th, 2013)

THIS FIRST AMENDMENT TO THE COLLABORATION AGREEMENT (this Amendment) is made to be effective as of January 19, 2011 (the Effective Date), by and between MacroGenics, Inc., a Delaware corporation (the Company) and Green Cross Corporation, a corporation organized under the laws of Korea (Green Cross). Capitalized terms used in this Amendment and not defined herein shall have the meanings given to such terms in the Agreement (as defined below).

Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Triple Asterisks Denote Omissions. FIRST AMENDMENT TO COLLABORATION AGREEMENT (August 2nd, 2013)

THIS FIRST AMENDMENT TO THE COLLABORATION AGREEMENT (this Amendment) is made to be effective as of January 19, 2011 (the Effective Date), by and between MacroGenics, Inc., a Delaware corporation (the Company) and Green Cross Corporation, a corporation organized under the laws of Korea (Green Cross). Capitalized terms used in this Amendment and not defined herein shall have the meanings given to such terms in the Agreement (as defined below).

Receptos Inc. – Second Amendment to Collaboration Agreement (April 4th, 2013)

This SECOND AMENDMENT (the Second Amendment), dated as of March 1, 2011, to that certain Collaboration Agreement dated December 20, 2010 (the Agreement) by and between Receptos, Inc., a Delaware corporation (Receptos) having its principal place of business at 10835 Road to the Cure, 2nd Floor, San Diego, CA 92121, and Eli Lilly and Company, an Indiana corporation (Lilly) having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 USA, is entered into by Receptos and Lilly (collectively, the Parties). The Parties agree to amend the Agreement as set forth herein:

Receptos Inc. – First Amendment to Collaboration Agreement (April 4th, 2013)

This AMENDMENT (the Amendment), dated as of March 14, 2011, to that certain Collaboration Agreement dated December 20, 2010 by and between Receptos, Inc., a Delaware corporation (Receptos) having its principal place of business at 10835 Road to the Cure, 2nd Floor, San Diego, CA 92121, and Eli Lilly and Company, an Indiana corporation (Lilly) having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 USA, (the Agreement) is entered into by Receptos and Lilly (collectively, the Parties). The Parties agree to amend the Agreement as set forth herein:

Receptos Inc. – Second Amendment to Collaboration Agreement (February 13th, 2013)

This SECOND AMENDMENT (the Second Amendment), dated as of March 1, 2011, to that certain Collaboration Agreement dated December 20, 2010 (the Agreement) by and between Receptos, Inc., a Delaware corporation (Receptos) having its principal place of business at 10835 Road to the Cure, 2nd Floor, San Diego, CA 92121, and Eli Lilly and Company, an Indiana corporation (Lilly) having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 USA, is entered into by Receptos and Lilly (collectively, the Parties). The Parties agree to amend the Agreement as set forth herein:

Receptos Inc. – First Amendment to Collaboration Agreement (February 13th, 2013)

This AMENDMENT (the Amendment), dated as of March 14, 2011, to that certain Collaboration Agreement dated December 20, 2010 by and between Receptos, Inc., a Delaware corporation (Receptos) having its principal place of business at 10835 Road to the Cure, 2nd Floor, San Diego, CA 92121, and Eli Lilly and Company, an Indiana corporation (Lilly) having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 USA, (the Agreement) is entered into by Receptos and Lilly (collectively, the Parties). The Parties agree to amend the Agreement as set forth herein:

Amendment to Collaboration Agreement (February 4th, 2013)

THIS AMENDMENT TO COLLABORATION AGREEMENT (the Amendment) is made and entered into as of September 20, 2012 (the Amendment Date), by and between UNIVERSAL BIOSENSORS PTY LTD., having a place of business at 1 Corporate Avenue, Rowville, Victoria 3178, Australia (UBI), and SIEMENS HEALTHCARE DIAGNOSTICS INC., having a place of business at 511 Benedict Avenue, Tarrytown, NY 10591, USA (Siemens).

Amendment to Collaboration Agreement (October 29th, 2012)

THIS AMENDMENT TO COLLABORATION AGREEMENT (the Amendment) is made and entered into as of September 20, 2012 (the Amendment Date), by and between UNIVERSAL BIOSENSORS PTY LTD., having a place of business at 1 Corporate Avenue, Rowville, Victoria 3178, Australia (UBI), and SIEMENS HEALTHCARE DIAGNOSTICS INC., having a place of business at 511 Benedict Avenue, Tarrytown, NY 10591, USA (Siemens).

MAP Pharmaceuticals – First Amendment to Collaboration Agreement (August 8th, 2011)

This FIRST AMENDMENT (this Amendment) to the Collaboration Agreement dated as of January 28, 2011 (the Agreement), by and among MAP Pharmaceuticals, Inc. (MAP), Allergan, USA, Inc. (Allergan USA), Allergan Sales, LLC (Allergan Sales) and Allergan, Inc., (collectively with Allergan USA and Allergan Sales, Allergan), is effective as of May 10, 2011 (the Effective Date), by and among Allergan and MAP. Capitalized terms not otherwise defined herein shall have the meanings provided for them the Agreement.

Allergan – First Amendment to Collaboration Agreement (August 3rd, 2011)

This First Amendment (this "Amendment") to the Collaboration Agreement dated as of January 28, 2011 (the "Agreement"), by and among MAP Pharmaceuticals, Inc. ("MAP"), Allergan, USA, Inc. ("Allergan USA"), Allergan Sales, LLC ("Allergan Sales") and Allergan, Inc., (collectively with Allergan USA and Allergan Sales, "Allergan"), is effective as of May 10, 2011 (the "Effective Date"), by and among Allergan and MAP. Capitalized terms not otherwise defined herein shall have the meanings provided for them the Agreement.

Quark Pharmaceuticals Inc – Amendment to Collaboration Agreement (November 24th, 2010)

This Amendment to the Collaboration Agreement (Amendment) is made as of May 25, 2006 (Effective Date) by and between Quark Biotech, Inc., a private limited company incorporated under the laws of California with a principal office at 6540 Kaiser Drive, Fremont, California 94555 (hereinafter Quark) and QBI Enterprises Ltd., a private company incorporated under the laws of the State of Israel with a principal office at Weizmann Science Park, P.O. Box 4071, Nes Ziona 70400, Israel (together hereinafter QBI), and Atugen AG, a company incorporated under the laws of Germany with a registered office at Robert-Rossle-Strasse 10, D-13125 Berlin, Germany (Atugen).

First Amendment to Collaboration Agreement (March 5th, 2010)

This First Amendment to Collaboration Agreement (this "First Amendment") is effective as of February 28, 2007 and is made by and between Takeda Pharmaceutical Company Limited, a Japanese corporation having offices at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (hereinafter "Takeda"); and XOMA (US) LLC, a Delaware limited liability company having offices at 2910 Seventh Street, Berkeley, California 94710, USA (hereinafter "XOMA").

Second Amendment to Collaboration Agreement (March 11th, 2009)

This Second Amendment to Collaboration Agreement (this Second Amendment) is effective as of February 9, 2009 (the Amendment Effective Date) and is made by and among Takeda Pharmaceutical Company Limited, a Japanese corporation having offices at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (hereinafter Takeda); XOMA (US) LLC, a Delaware limited liability company having offices at 2910 Seventh Street, Berkeley, California 94710, USA (hereinafter XOMA) [*]

Pdl Biopharma – First Amendment to Collaboration Agreement (November 7th, 2007)

THIS FIRST AMENDMENT TO COLLABORATION AGREEMENT (the Amendment) amends the Collaboration Agreement entered into as of September 12, 2005 (the Agreement) by and between PDL BioPharma, Inc. (formerly Protein Design Labs, Inc.), a Delaware corporation (PDL), and Biogen Idec MA Inc., a Massachusetts corporation (Biogen Idec).

First Amendment to Collaboration Agreement (August 7th, 2007)

This First Amendment to the Collaboration Agreement is effective as of June 5, 2007 (the First Amendment Effective Date) between EXELIXIS, INC., a Delaware corporation having its principal place of business at 170 Harbor Way, P.O. Box 511, South San Francisco, California 94083-0511 USA (Exelixis) and DAIICHI SANKYO COMPANY LIMITED, (formerly known as Sankyo Company, Limited), a Japanese corporation having its principal place of business at 3-5-1 Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426 Japan (Daiichi-Sankyo).

First Amendment to Collaboration Agreement (May 10th, 2007)

This First Amendment to Collaboration Agreement (this First Amendment) is effective as of February 28, 2007 and is made by and between Takeda Pharmaceutical Company Limited, a Japanese corporation having offices at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (hereinafter Takeda); and XOMA (US) LLC, a Delaware limited liability company having offices at 2910 Seventh Street, Berkeley, California 94710, USA (hereinafter XOMA).

Quark Pharmaceuticals Inc – Amendment to Collaboration Agreement (April 16th, 2007)

This Amendment to the Collaboration Agreement (Amendment) is made as of May 25, 2006 (Effective Date) by and between Quark Biotech, Inc., a private limited company incorporated under the laws of California with a principal office at 6540 Kaiser Drive, Fremont, California 94555 (hereinafter Quark) and QBI Enterprises Ltd., a private company incorporated under the laws of the State of Israel with a principal office at Weizmann Science Park, P.O. Box 4071, Nes Ziona 70400, Israel (together hereinafter QBI), and Atugen AG, a company incorporated under the laws of Germany with a registered office at Robert-Rossle-Strasse 10, D-13125 Berlin, Germany (Atugen).

Amendment to Collaboration Agreement (February 26th, 2007)

THIS AMENDMENT TO COLLABORATION AGREEMENT (the Amendment) is entered into and effective as of October 31, 2006 (the Amendment Date) for the purpose of amending that certain Collaboration Agreement dated September 19, 2002, as amended (the Agreement) by and between:

Avalon Pharmaceuticals, Inc. – First Amendment to Collaboration Agreement (November 8th, 2006)

THIS FIRST AMENDMENT dated as of the 21st day of September, 2006 (the First Amendment) is made between Avalon Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 20358 Seneca Meadows Parkway, Germantown, Maryland 20876 (Avalon) and ChemDiv, Inc., a Wisconsin corporation having its principal office at 11558 Sorrento Valley Road,, San Diego, California 92121 (ChemDiv, and together with Avalon, the Parties).